Tau (phospho T217) Recombinant Rabbit mAb (S-176-213)

Tau (phospho T217) refers to a specific form of the Tau protein that has undergone phosphorylation at its 217th threonine residue. This modification has been recognized as a highly promising biomarker for Alzheimer's disease (AD) and other tauopathies. In healthy neurons, Tau protein stabilizes the cytoskeleton by binding to microtubules, and its function is tightly regulated by phosphorylation levels. However, under pathological conditions, hyperphosphorylation at sites such as T217 significantly impairs Tau's ability to bind to microtubules, leading to its misfolding, aggregation, and ultimately the formation of neurofibrillary tangles—one of the core pathological hallmarks of AD. Notably, phosphorylation at T217 is markedly elevated in the very early stages of the disease, even before symptoms appear, and its abnormal levels closely correlate with the distribution of tangles and cognitive decline. Due to its high specificity and sensitivity, detection methods such as cerebrospinal fluid assays and emerging positron emission tomography (PET) imaging are currently being utilized to measure Tau (phospho T217), aiming to achieve early and accurate diagnosis of AD as well as monitoring of disease progression.